Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 3/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10301843 | 0.98 | CRBN (0.34) | CRBNTLR4TLR2ACACBPDE2A | |
| SCHEMBL12889169 | 0.97 | PDE2A (0.33) | CRBNTLR4TLR2ACACBPDE2A | |
| SCHEMBL12889170 | 0.97 | PDE2A (0.33) | CRBNTLR4TLR2ACACBPDE2A | |
| SCHEMBL10301845 | 0.97 | PDE2A (0.33) | CRBNTLR4TLR2ACACBPDE2A | |
| SCHEMBL10301841 | 0.92 | HPGD (0.32) | PPARD | |
| SCHEMBL10301849 | 0.90 | MAPT (0.31) | — | |
| SCHEMBL10301848 | 0.89 | ACACB (0.31) | ACACB | |
| SCHEMBL14765832 | 0.89 | CRBN (0.33) | CRBNTLR4TLR2SCN9APPARG | |
| SCHEMBL12734168 | 0.89 | CRBN (0.34) | CRBNTLR4TLR2SCN9A | |
| SCHEMBL14765847 | 0.88 | TLR4 (0.33) | CRBNTLR4TLR2ACACBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | CRBN 1642/4885TLR4 3894/4885TLR2 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.